Dyadic International, Inc. (DYAI)

Market Cap	57.11M
Revenue (ttm)	3.36M
Net Income (ttm)	-6.33M
Shares Out	29.59M
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	225,122
Open	1.700
Previous Close	1.670
Day's Range	1.680 - 2.040
52-Week Range	0.930 - 2.670
Beta	0.72
Analysts	Strong Buy
Price Target	6.00 (+210.88%)
Earnings Date	Nov 12, 2024

About DYAI

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein p...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 5, 2004
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: DYAI
• Website: https://www.dyadic.com

Financial Performance

In 2023, Dyadic International's revenue was $2.90 million, a decrease of -1.07% compared to the previous year's $2.93 million. Losses were -$6.80 million, -30.20% less than in 2022.

Analyst Forecast

According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target

$6.0

(210.88% upside)

Analyst Consensus: Strong Buy